Alzheimer’s trial drug tideglusib helps rat teeth regrow dentin

Tideglusib, a drug first tested in people with Alzheimer’s disease, helped rat teeth fill drilled holes with new dentin, in a 2020 King’s College London study in the Journal of Dental Research. Dentin is the hard tissue that lies under the enamel. The drug sat on a small collagen sponge over the exposed pulp (the soft, living core of the tooth), and the tooth’s own stem cells built a bridge of new dentin across the damage. The results come from mice and rats, and the team still had to drill the hole first, as a dentist does to remove decay.

How tideglusib helps a tooth repair itself

Teeth already have a small repair system. When the pulp is exposed, stem cells inside it turn into new dentin-making cells and lay down a thin band of repair dentin, but this band is too small to fix large holes, according to the team’s first paper on the method in Scientific Reports. Dentists therefore fill deep holes with mineral cements that never break down, so the lost dentin is never fully replaced, the same paper explains.

According to the same paper, tideglusib blocks an enzyme called GSK-3 (glycogen synthase kinase 3). Blocking it switches on Wnt signalling, a chain of chemical messages that cells use to start repair, and this pushes more pulp stem cells to become dentin-making cells. The idea is to boost the tooth’s own repair until new dentin fills the hole.

First test: mouse teeth filled with their own dentin

In the first study, the team led by Paul Sharpe drilled 0.13 mm holes into the upper first molars of mice to expose the pulp, the Scientific Reports paper found. Each hole received a piece of collagen sponge, a material already approved for dental use, soaked in 50 nM tideglusib or one of two other GSK-3 blockers, BIO and CHIR99021, according to the same paper. A layer of glass ionomer cement then sealed the tooth. The authors examined six to nine teeth per time point, and the study was neither blinded nor randomized, the paper notes.

After 4 and 6 weeks, teeth treated with the three drugs held on average twice as much mineral at the injury site as teeth given the sponge alone, the paper reports. The same paper found 1.7 times more mineral than in teeth capped with MTA (mineral trioxide aggregate, a standard dental cement). By 6 weeks, new dentin in the tideglusib teeth filled the whole hole, the sponge had broken down, and the pulp was still alive, the same study found.

Scaling up to rat teeth

The 2020 study moved the method to adult male Wistar rats, whose molars allow a larger wound, the paper explains. A carbide drill 0.25 mm wide opened the pulp, and a sponge carrying 0.1 microlitre of 1 micromolar tideglusib was placed on it, according to the same paper. The authors calculate that this is about 0.03 ng (billionths of a gram) of drug per tooth. Other teeth received CHIR99021 or only the solvent, DMSO, the paper reports.

After 4 weeks, scans and tissue slices showed a dentin bridge in the tideglusib and CHIR99021 teeth, and no bridge in the solvent-only teeth, the paper found. Tideglusib teeth held 0.113 mg of new mineral, against 0.062 mg in the solvent group, the same paper reports. The volume of new dentin was 0.055 mm3 with tideglusib and 0.017 mm3 without a drug, the study found, with three to four teeth per group.

The wound in rats was 9.7 times larger in area than in mouse teeth, the paper reports, which is the source of the “up to 10 times larger” figure in the study and its press coverage. The first version of this article described it as ten times larger than the holes teeth can repair on their own, a comparison the paper does not make. According to the authors, the rat repair covered about 0.1 mm2, which matches a small pulp wound in people, while most pulp wounds found during decay removal in humans measure 0.01 to 2 mm2.

Is the new dentin like natural dentin?

The team used Raman microspectroscopy, a laser method that reads the chemical makeup of a tissue. The new dentin had the same carbonate-to-phosphate and mineral-to-protein ratios as natural dentin, and both differed from the jawbone around the teeth, the 2020 paper reports. The only difference the authors found was a slightly more crystalline mineral in the new dentin.

These chemical tests were run on mouse teeth, and the methods list BIO, one of the other GSK-3 blockers, as the drug used in mice. The chemical match was therefore shown for this family of drugs, and the paper does not report the same test on dentin grown with tideglusib.

The drug’s effect stayed close to the wound

A tooth drug should act only where the damage is. In rats, 24 hours after treatment, a gene that signals Wnt activity (Axin2) rose in the pulp of the crown, and not in the root pulp or in the undamaged tooth next to it, the 2020 paper found. The rise was 3.9-fold with CHIR99021 and 1.4-fold with tideglusib, and the tideglusib rise was not statistically significant, according to the same paper.

If the whole dose on the sponge reached the blood, the authors estimate a level of 0.08 pmol/L for tideglusib, well below the doses given in clinical trials. The 2017 paper made the same point: each mouse tooth received at most 21 pg (trillionths of a gram) of tideglusib, while Alzheimer’s trials gave 500 to 1,000 mg a day for 26 weeks. Tideglusib did not become an Alzheimer’s treatment: a later placebo-controlled trial in people with mild to moderate disease found it acceptably safe but of no clinical benefit, the trial report concluded.

A test in dog teeth and the limits so far

Update (2025): an independent team of Egyptian researchers tested tideglusib on larger teeth, in a dog study published in BMC Oral Health. The researchers exposed the pulp of 56 teeth in two dogs, and capped half with a collagen sponge soaked in tideglusib and half with MTA, the paper reports. The methods give the tideglusib dose as 50 nM in one passage and 30 nM in another, the same paper shows. After 3 and 8 weeks, tideglusib teeth showed more inflammatory cells and more disorganized pulp than MTA teeth, the same study found. No tooth formed new hard tissue at 3 weeks, and at 8 weeks only two MTA teeth showed partial new hard tissue, against none with tideglusib, according to the same paper. The difference between the two materials was not statistically significant, the authors report.

The King’s College London results come from small groups of healthy rodent teeth drilled in the lab, without real decay or bacteria. According to the university’s news release on the rat study, human trials were not expected to begin at that stage. The same group later moved to NP928, a newer and more water-soluble drug of the same family, placed by syringe in a gel that sets under a dental blue light, and a later Journal of Dental Research paper reports better dentin repair in mice than with the sponge.

Tideglusib aims to repair the inside of an existing tooth. Separate work aims to grow whole new teeth: Japan begins clinical trials for tooth regrowth treatment, and another Gromeus article explains how a drug to regrow teeth moves closer to clinical use.

Sources and related information

Journal of Dental Research – Translation Approach for Dentine Regeneration Using GSK-3 Antagonists – 2020

Zaugg, Banu, Walther, Chandrasekaran, Babb, Salzlechner, Hedegaard, Gentleman, and Sharpe report the rat experiments, the Raman comparison with natural dentin and bone, and the Axin2 tests in crown and root pulp (J Dent Res 2020;99(5):544-551). The paper is published under DOI 10.1177/0022034520908593, and the open-access full text is on PubMed Central.

Scientific Reports – Promotion of natural tooth repair by small molecule GSK3 antagonists – 2017

Neves, Babb, Chandrasekaran, and Sharpe describe the first mouse experiments with tideglusib, BIO, and CHIR99021 on collagen sponges, compared with the sponge alone and with MTA (Sci Rep 2017;7:39654). The full text is available under DOI 10.1038/srep39654.

BMC Oral Health – Pulp response following direct pulp capping with Tideglusib and mineral trioxide aggregate: an animal study – 2025

This dog study compares tideglusib on a collagen sponge with MTA as a direct pulp cap and reports more inflammation with tideglusib and no difference in new hard tissue. It is open access under DOI 10.1186/s12903-025-06546-6.

Journal of Alzheimer’s Disease – A phase II trial of tideglusib in Alzheimer’s disease – 2015

Lovestone and colleagues report the placebo-controlled ARGO trial, which found tideglusib acceptably safe but without clinical benefit in mild to moderate Alzheimer’s disease. The abstract is on the journal’s DOI page.

King’s College London – Further evidence shows clinical viability of natural tooth repair method – 2020

The university’s news release on the rat study summarises the findings and states that human trials were not expected at that stage.

Journal of Dental Research – GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel – 2021

Alaohali, Salzlechner, and colleagues at King’s College London describe NP928, a water-soluble drug of the same family as tideglusib, delivered in a hyaluronic acid gel set with dental blue light and tested in mouse teeth. The open-access paper is under DOI 10.1177/00220345211020652.

Leave a Reply

Your email address will not be published. Required fields are marked *